Oisin Biotechnologies

From H+Pedia
Jump to navigation Jump to search

Oisin Biotechnologies (or, more briefly, Oisin) is a startup in the field of rejuvenation biotechnology that is developing a genetically-targeted intervention to clear senescent cells.

Oisin was founded by Gary Hudson and Matthew Scholz.[1].

Oisin is one of the first companies to receive funding as part of the SENS Project 21 funding initiative, with funding provided by Michael Greve[2].

Oisin is described as follows on its own website:[3]

When cells detect that they have been irretrievably damaged, they enter a non-dividing condition known as cell-cycle arrest, or senescence. It’s believed this occurs to prevent cells from going “rogue” and turning cancerous. Ideally, they should die by the process known as apoptosis, but in this case, they don’t. They become “zombie cells” – unable to kill themselves or resume normal function. Senescent cells secrete molecules that cause inflammation in an effort to attract immune cells that would usually clear them. But for reasons that are not fully known, as we age, persistently senescent cells accumulate, leading to a large number of age-related diseases.

Oisín is developing a genetically-targeted intervention to clear these cells. As a recent study has shown, clearing senescent cells both reduces negative effects of aging pathologies and also extends median lifespan and survival.

External links